ABSTRACT
Combination therapy comprising natural polyphenols and anticancer drugs has been used to decrease the adverse effects and increase the effectiveness and antioxidant activities of the drugs. The antioxidant and anticancer effects of quercetin (Q), a nutritive polyphenol, have been observed both in vitro and in vivo. Likewise, the anticancer activity of sulfamethoxazole (S) has been demonstrated in vitro and in vivo. This study aimed to investigate the in vitro and in vivo anticancer effects of Q alone and in combination with S. The in vitro effects of S, Q, and S + Q on HCT-116, HepG2, MCF-7, and PC3 cell lines were examined. Additionally, the in vivo effects of these drugs were evaluated using Ehrlich ascites carcinoma (EAC) tumor-bearing mice. The in vitro data revealed the potent anticancer activity of S + Q through the induction of apoptosis and cell cycle arrest. The EAC-inoculated mice treated with S + Q presented with elevated SOD, GSH, CAT, and TAC levels and decreased malondialdehyde levels compared with the untreated EAC group, thus revealing the antioxidant and protective actions of S + Q against EAC cell invasion. Furthermore, the downregulation of NFkB and upregulation of the caspase3 gene in the EAC-inoculated mice treated with the S + Q indicated the induction of the apoptotic pathway and decrease in both cell proliferation and metastasis. In conclusion, the combination of S and Q might exert anticancer effects by inducing apoptosis and exhibiting selective toxicity against the cancer cells and thereby protecting the vital organs.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Carcinoma, Ehrlich Tumor/drug therapy , Cell Proliferation/drug effects , Animals , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Apoptosis/drug effects , Caspase 3/metabolism , Cell Cycle Checkpoints/drug effects , Female , Gene Expression Regulation, Neoplastic/drug effects , HCT116 Cells , Hep G2 Cells , Humans , MCF-7 Cells , Mice , NF-kappa B/metabolism , PC-3 Cells , Quercetin/administration & dosage , Sulfamethoxazole/administration & dosageABSTRACT
OBJECTIVE: The purpose of this study was to determine the clinical value of triple antibiotic therapy consisting of doxycycline, compound sulfamethoxazole and rifampicin in the treatment of brucellosis spondylitis. METHODS: A retrospective analysis was performed on 100 patients with brucellosis spondylitis admitted to the First Affiliated Hospital of Hebei North University from March 2016 to June 2019. Patients were divided into the following two groups: the control group (n = 50) treated with dual antibiotic therapy (rifampicin + compound sulfamethoxazole), and the observation group (n = 50) treated with triple antibiotic therapy (rifampicin + doxycycline + compound sulfamethoxazole). The treatment effect, low back pain relief, levels of erythrocyte sedimentation rate (ESR), procalcitonin (PCT) and C-reactive protein (CRP), as well as the adverse reactions were compared between the two groups. RESULTS: The response rate of the observation group was significantly higher than that of the control group (P < 0.05). Before treatment, there was no significant difference in the low back pain assessed by the visual analogue scale (VAS), or levels of ESR, PCT and CRP between the two groups (P > 0.05). But after treatment, the VAS score and the levels of ESR, PCT and CRP in observation group were lower than those in the control group (P < 0.05). No significant difference was found in the incidence of adverse reactions (P > 0.05). CONCLUSION: The triple antibiotic therapy of doxycycline, compound sulfamethoxazole and rifampicin is effective in the treatment of brucellosis spondylitis. It can significantly alleviate patients' back pain and inflammation with a high safety profile, which is worthy of clinical application.
Subject(s)
Brucellosis/drug therapy , Doxycycline/therapeutic use , Rifampin/therapeutic use , Spondylitis/drug therapy , Sulfamethoxazole/therapeutic use , Adult , Brucellosis/metabolism , Doxycycline/administration & dosage , Drug Therapy, Combination , Female , Humans , Inflammation/drug therapy , Inflammation/metabolism , Low Back Pain/drug therapy , Low Back Pain/metabolism , Male , Retrospective Studies , Rifampin/administration & dosage , Spondylitis/metabolism , Sulfamethoxazole/administration & dosageABSTRACT
OBJECTIVE: Nocardia kroppenstedtii was isolated from the spinal vertebral abscess of a 78-year-old patient presenting with mid-thoracic pain and bilateral lower limb weakness and numbness. The patient was on long-term immunosuppressive therapy with steroids for underlying autoimmune hemolytic anemia. Investigations showed a T5 pathological fracture and vertebra plana with the erosion of the superior and inferior endplates. There was evidence of paraspinal collection from the T4-T6 vertebrae with an extension into the spinal canal. Analysis of Nocardia 16S rRNA (99.9%, 1395/1396 nt) and secA1 gene (99.5%, 429/431 nt) fragments showed the highest sequence similarity with Nocardia kroppenstedtii type strain (DQ157924), and next with Nocardia farcinica (Z36936). The patient was treated with intravenous carbapenem and oral trimethoprim-sulfamethoxazole for four weeks, followed by another six months of oral trimethoprim-sulfamethoxazole. Despite the improvement of neurological deficits, the patient required assistive devices to ambulate at discharge. This study reports the first isolation of N. kroppenstedtii from the spinal vertebral abscess of a patient from Asia. Infections caused by N. kroppenstedtii may be underdiagnosed as the bacterium can be misidentified as N. farcinica in the absence of molecular tests in the clinical laboratory.
Subject(s)
Epidural Abscess/microbiology , Nocardia Infections/microbiology , Nocardia/isolation & purification , Administration, Oral , Aged , Anemia, Hemolytic, Autoimmune/drug therapy , Anemia, Hemolytic, Autoimmune/microbiology , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacology , Epidural Abscess/drug therapy , Female , Humans , Immunosuppressive Agents/therapeutic use , Nocardia/drug effects , Nocardia Infections/drug therapy , Steroids/therapeutic use , Sulfamethoxazole/administration & dosage , Sulfamethoxazole/pharmacology , Trimethoprim/administration & dosage , Trimethoprim/pharmacologyABSTRACT
Escherichia coli is an important model organism in microbiology and a prominent member of the human microbiota1. Environmental isolates readily colonize the gastrointestinal tract of humans and other animals, and they can serve diverse probiotic, commensal and pathogenic roles in the host2-4. Although certain strains have been associated with the severity of inflammatory bowel disease (IBD)2,5, the diverse immunomodulatory phenotypes remain largely unknown at the molecular level. Here, we decode a previously unknown E. coli metabolic pathway that produces a family of hybrid pterin-phenylpyruvate conjugates, which we named the colipterins. The metabolites are upregulated by subinhibitory levels of the antifolate sulfamethoxazole, which is used to treat infections including in patients with IBD6,7. The genes folX/M and aspC/tyrB involved in monapterin biosynthesis8-10 and aromatic amino acid transamination,11 respectively, were required to initiate the colipterin pathway. We show that the colipterins are antioxidants, harbour diverse immunological activities in primary human tissues, activate anti-inflammatory interleukin-10 and improve colitis symptoms in a colitis mouse model. Our study defines an antifolate stress response in E. coli and links its associated metabolites to a major immunological marker of IBD.
Subject(s)
Antioxidants/metabolism , Escherichia coli/metabolism , Immunomodulation , Pteridines/metabolism , Sulfamethoxazole/metabolism , Animals , Antioxidants/administration & dosage , Antioxidants/chemistry , Antioxidants/pharmacology , Cells, Cultured , Colitis/drug therapy , Colitis/microbiology , Disease Models, Animal , Escherichia coli/genetics , Escherichia coli/physiology , Escherichia coli Proteins/genetics , Escherichia coli Proteins/metabolism , Gastrointestinal Microbiome , Humans , Interleukin-10/metabolism , Metabolic Networks and Pathways , Mice , Oxidation-Reduction , Pteridines/administration & dosage , Pteridines/chemistry , Pteridines/pharmacology , Stress, Physiological , Sulfamethoxazole/administration & dosageABSTRACT
Extracorporeal membrane oxygenation (ECMO) therapy could affect drug concentrations via adsorption onto the oxygenator and/or associated circuit. We describe a case of a 33-year-old man with severe respiratory failure due to Pneumocystis jirovecii infection on a background of recently diagnosed human immunodeficiency virus infection. He required venovenous ECMO therapy for refractory respiratory failure. Intravenous sulfamethoxazole-trimethoprim (100 and 20 mg/kg/day) was administered in a dosing regimen every 6 hours. Pre-oxygenator, post-oxygenator, and arterial blood samples were collected after antibiotic administration and were analyzed for total sulfamethoxazole and trimethoprim concentrations. The peak sulfamethoxazole and trimethoprim concentrations were 122 mg/L and 5.3 mg/L, respectively. The volume of distribution for sulfamethoxazole was 0.37 and 2.30 L/kg for trimethoprim. The clearance for sulfamethoxazole was 0.35 ml/minute/kg and for trimethoprim was 1.64 ml/minute/kg. The pharmacokinetics of sulfamethoxazole and trimethoprim appear not to be affected by ECMO therapy, and dosing adjustment may not be required.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Respiratory Insufficiency/therapy , Sulfamethoxazole/therapeutic use , Trimethoprim/therapeutic use , Adult , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacokinetics , Area Under Curve , Drug Therapy, Combination , Extracorporeal Membrane Oxygenation , Humans , Infusions, Intravenous , Male , Pneumocystis carinii , Sulfamethoxazole/administration & dosage , Sulfamethoxazole/pharmacokinetics , Trimethoprim/administration & dosage , Trimethoprim/pharmacokineticsABSTRACT
Nocardia species usually cause opportunistic infections, and the frequency of these infections is increasing owing to the growing population of immunocompromised hosts. However, Nocardia may sometimes causes an infectious disease in immunocompetent hosts. Herein, we report two cases of pulmonary nocardiasis in immunocompetent individuals, whose chest computed tomography (CT) findings mimicked bronchiectasis. Samples of bronchalveolar lavage (BAL) fluid obtained by bronchoscopy showed filamentous, branching, gram-positive rods, acid-fast filamentous branching rods, and a colony of suspected Nocardia was cultured. Based on 16sRNA and hsp65 gene sequence analysis, case 1 was identified as N. cyriacigeorgica, but case 2 was not matched. The patients responded well to treatment with the combination of sulfamethoxazole and linezolid.
Subject(s)
Bronchiectasis/diagnostic imaging , Linezolid/therapeutic use , Nocardia Infections/diagnostic imaging , Nocardia Infections/drug therapy , Sulfamethoxazole/administration & dosage , Tomography, X-Ray Computed/methods , Bronchiectasis/diagnosis , Diagnosis, Differential , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Immunocompetence/immunology , Male , Middle Aged , Nocardia/drug effects , Nocardia/isolation & purification , Nocardia Infections/diagnosis , Risk Assessment , Severity of Illness Index , Treatment OutcomeABSTRACT
A comprehensive ecotoxicological evaluation of a sulfamethazine (SMZ) and sulfamethoxazole (SMX) mixture was conducted using an indicator microalga, Scenedesmus obliquus. The toxicological effects of this mixture were studied using microalgal growth patterns, biochemical characteristics (total chlorophyll, carotenoid, carbohydrate, fatty acid methyl ester), and elemental and Fourier-transform infrared spectroscopy analyses. The 96-h half maximal effective concentration (EC50) of the SMZ and SMX mixture was calculated to be 0.15â¯mgâ¯L-1 according to the dose-response curves obtained. The chlorophyll content decreased with elevated SMZ and SMX concentrations, while the carotenoid content initially increased and then decreased as concentration raised. The unsaturated fatty acid methyl esters (FAMEs) content was enhanced with higher SMZ and SMX concentrations, while that of saturated FAMEs simultaneously decreased due to SMZ and SMX stress. Elemental analyses showed an improved percentage of nitrogen and sulfur in the microalgal biomass as SMZ and SMX concentrations increased. The microalga S. obliquus was shown to biodegrade the chemicals tested and removed 31.4-62.3% of the 0.025-0.25â¯mg SMZ L-1 and 27.7-46.8% of the 0.025-0.25â¯mg SMX L-1 in the mixture after 12 days of cultivation. The greater biodegradation observed at higher SMZ and SMX concentrations indicates that microalgal degradation of SMZ and SMX could act as an efficient adaptive mechanism to antibiotics.
Subject(s)
Microalgae/drug effects , Scenedesmus/drug effects , Sulfamethazine/toxicity , Sulfamethoxazole/toxicity , Biodegradation, Environmental , Carbohydrates/analysis , Chlorophyll/metabolism , Dose-Response Relationship, Drug , Ecotoxicology/methods , Fatty Acids/metabolism , Microalgae/metabolism , Nitrogen/analysis , Nitrogen/metabolism , Scenedesmus/growth & development , Scenedesmus/metabolism , Sulfamethazine/administration & dosage , Sulfamethoxazole/administration & dosage , Sulfur/metabolism , Water Pollutants, Chemical/toxicityABSTRACT
BACKGROUND: Varicella-zoster virus (VZV) causes herpes zoster. Pneumocystis jirovecii (PJ) also causes pneumonia in immunocompromised hosts. Although both cause opportunistic infections, it is rare to have a co-infection in a non-human immunodeficiency virus carrier. CASE PRESENTATION: An 84-year-old woman with hemolytic anemia referred because of acute respiratory failure. She had received prednisolone without PJ pneumonia prevention. She developed dyspnea and desaturation while eating, and thus was treated based on a presumptive diagnosis of aspiration pneumonia. Physical examination revealed a vesicular rash on the left side of her neck suggesting herpes zoster infection. Polymerase chain reaction of her sputum for PJ and VZV was positive, which confirmed a diagnosis of pneumonia due to PJ and VZV co-infection. Despite acyclovir and sulfamethoxazole and trimethoprim administration, she died on hospital day 19. CONCLUSIONS: Clinicians should suspect PJP when patients on systemic corticosteroids develop pneumonia and they have not received prophylactic treatment for PJP in non-HIV carriers. When such patients have a VZV rash, clinicians should aggressively seek signs of opportunistic infections. Our case hereby highlights the importance of recognizing the possibility of a VZV and PJ co-infection.
Subject(s)
Coinfection/microbiology , Coinfection/virology , Herpes Zoster/diagnosis , Herpesvirus 3, Human/genetics , Immunocompromised Host/immunology , Pneumocystis carinii/genetics , Pneumonia, Pneumocystis/diagnosis , Varicella Zoster Virus Infection/diagnosis , Acyclovir/administration & dosage , Acyclovir/therapeutic use , Aged, 80 and over , Anti-Infective Agents, Urinary/administration & dosage , Anti-Infective Agents, Urinary/therapeutic use , Antiviral Agents/administration & dosage , Antiviral Agents/therapeutic use , Coinfection/drug therapy , Fatal Outcome , Female , Herpes Zoster/drug therapy , Herpesvirus 3, Human/isolation & purification , Humans , Opportunistic Infections/drug therapy , Opportunistic Infections/microbiology , Opportunistic Infections/virology , Pneumocystis carinii/isolation & purification , Pneumonia, Pneumocystis/drug therapy , Polymerase Chain Reaction , Sputum/microbiology , Sputum/virology , Sulfamethoxazole/administration & dosage , Sulfamethoxazole/therapeutic use , TrimethoprimABSTRACT
Background: Myroides spp. are common environmental organisms and they can be isolated predominantly in water, soil, food and in sewage treatment plants. In the last two decades, an increasing number of infections such as urinary tract infections and skin and soft tissue infections, caused by these microorganisms has been reported. Selection of appropriate antibiotic therapy to treat the infections caused by Myroides spp. is difficult due to the production of a biofilm and the organism's intrinsic resistance to many antibiotic classes. Case presentation: We report the case of a 69-year-old immunocompromised patient who presented with repeated episodes of macroscopic haematuria, from Northern Italy.A midstream urine sample cultured a Gram negative rod in significant amounts (> 105 colony-forming units (cfu)/mL), which was identified as Myroides odoratimimus. The patient was successfully treated with trimethoprim/sulfamethoxazole after antibiotic susceptibility testing confirmed its activity. Conclusion: This case underlines the emergence of multidrug resistant Myroides spp. which are ubiquitous in the environment and it demands that clinicians should be more mindful about the role played by atypical pathogens, which may harbour or express multidrug resistant characteristics, in immunocompromised patients or where there is a failure of empiric antimicrobial therapy.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Drug Resistance, Multiple, Bacterial , Flavobacteriaceae Infections/microbiology , Flavobacteriaceae/drug effects , Flavobacteriaceae/isolation & purification , Urinary Tract Infections/microbiology , Aged , Flavobacteriaceae/genetics , Flavobacteriaceae/physiology , Flavobacteriaceae Infections/drug therapy , Flavobacteriaceae Infections/immunology , Humans , Immunocompromised Host , Male , Microbial Sensitivity Tests , Sulfamethoxazole/administration & dosage , Trimethoprim/administration & dosage , Urinary Tract Infections/drug therapy , Urinary Tract Infections/immunologyABSTRACT
Frequent use of broad-spectrum antimicrobial classes has been reported in Japan; however, little is known about the long-term trend of national antimicrobial consumption, and that of individual agents. This study analyzed the national sales data of systemic antimicrobials from 2004 to 2016, derived from the IMS Japan Pharmaceutical Market database, to assess the consumption patterns of antimicrobial classes and agents in Japan. The number of defined daily doses per 1000 inhabitants per day (DID) was calculated for each antimicrobial agent. During the last 13 years, total antimicrobial consumption fluctuated by only 5% around the average of 14.41 DID. In 2016, the most used class was macrolides (32%), followed by cephalosporins (28%) and fluoroquinolones (19%). Oral agents comprised a large proportion (93%) of antimicrobial consumption. The most used agent, clarithromycin, accounted for 25% of all oral compounds used in 2016. The consumption of oral agents with high bioavailability, such as fluoroquinolones, amoxicillin, and sulfamethoxazole/trimethoprim increased, whereas that of cephalosporins decreased. In 2016, ceftriaxone was the most consumed parenteral agent, followed by cefazolin. The consumption of parenteral agents increased after 2009 when high-dose regimens of piperacillin/tazobactam, meropenem, and ampicillin/sulbactam were approved by the health insurance system. National antimicrobial consumption has been stable over the last 13 years. Moreover, shifts in the use of agents with high bioavailability and those approved for high-dose regimens were observed. However, the increased use of broad-spectrum agents is worrisome. A multifaceted approach is required to reduce overall antimicrobial consumption.
Subject(s)
Anti-Infective Agents/administration & dosage , Anti-Infective Agents/therapeutic use , Bacterial Infections/drug therapy , Drug Utilization/trends , Infusions, Parenteral/trends , Administration, Oral , Amoxicillin/administration & dosage , Amoxicillin/therapeutic use , Bacterial Infections/epidemiology , Ceftriaxone/administration & dosage , Ceftriaxone/therapeutic use , Cephalosporins/administration & dosage , Cephalosporins/therapeutic use , Clarithromycin/administration & dosage , Clarithromycin/therapeutic use , Fluoroquinolones/administration & dosage , Fluoroquinolones/therapeutic use , Humans , Infusions, Parenteral/statistics & numerical data , Japan , Macrolides/administration & dosage , Macrolides/therapeutic use , Product Surveillance, Postmarketing , Sulfamethoxazole/administration & dosage , Sulfamethoxazole/therapeutic use , World Health OrganizationABSTRACT
OBJECTIVES: Trimethoprim/sulfamethoxazole (TMP/SMX) and clindamycin are frequently prescribed to treat cellulitis. The primary objective was to determine if weight-based dosing of these antibiotics is associated with better outcomes in cellulitis. The secondary objective was to assess variables associated with clinical failure among hospitalized patients with cellulitis with or without cutaneous abscess. METHODS: This multi-center retrospective cohort study was conducted from January 1, 2010 to September 4, 2014. Adult patients admitted for cellulitis who received a minimum of seven days of therapy and discharged on oral clindamycin or TMP/SMX were included. Binary univariate and multivariate logistic regression analyses were performed to identify risk factors for clinical failure, including the impact of dose adequacy of clindamycin and TMP/SMX on clinical outcomes. RESULTS: A total of 208 cases met inclusion criteria. Of these cases, 120 (57.7%) received inadequate dosing of clindamycin (<10 mg/kg/day) or TMP/SMX (<5 mg TMP/kg per day) while 88 (42.3%) received adequate dosing. Clinical failure occurred in 36/120 (30%) and 15/88 (17%) of patients receiving inadequate and adequate doses, respectively (p = 0.032). Upon univariate analysis length of stay ≥ 7 days (OR = 2.96, p = 0.046) and inadequate dosing (OR = 2.09, p = 0.034) were associated with clinical failure. Upon multivariate analysis, inadequate dosing was independently associated with clinical failure (OR = 2.01, p = 0.032). CONCLUSION: Inadequate dosing of clindamycin and TMP/SMX is independently associated with clinical failure in patients hospitalized with cellulitis. Further prospective studies evaluating weight-based dosing of clindamycin and TMP/SMX in the setting of cellulitis are warranted.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Cellulitis/drug therapy , Clindamycin/administration & dosage , Staphylococcal Skin Infections/drug therapy , Sulfamethoxazole/administration & dosage , Trimethoprim/administration & dosage , Administration, Oral , Aged , Body Weight , Cohort Studies , Dose-Response Relationship, Drug , Hospitalization , Humans , Logistic Models , Male , Middle Aged , Multivariate Analysis , Retrospective Studies , Risk Factors , Treatment OutcomeABSTRACT
Biliary atresia is progressive fibro-inflammatory cholangiopathy of young children. Central to pathogenic mechanisms of injury is the tissue targeting by the innate and adaptive immune cells. Among these cells, neutrophils and the IL-8/Cxcl-8 signaling via its Cxcr2 receptor have been linked to bile duct injury. Here, we aimed to investigate whether the intestinal microbiome modulates Cxcr2-dependent bile duct injury and obstruction. Adult wild-type (WT) and Cxcr2-/- mice were fed a diet supplemented with sulfamethoxazole/trimethoprim (SMZ/TMP) during pregnancy and lactation, and their pups were injected intraperitoneally with rhesus rotavirus (RRV) within 24 hours of life to induce experimental biliary atresia. The maternal exposure to SMZ/TMP significantly lowered the incidence of jaundice and bile duct obstruction and resulted in improved survival, especially in Cxcr2-/- mice. Analyses of the microbiome by deep sequencing of 16S rRNA of the neonatal colon showed a delay in bacterial colonization of WT mice induced by SMZ/TMP, with a notable switch from Proteobacteria to Firmicutes. Interestingly, the genetic inactivation of Cxcr2 alone produced a similar bacterial shift. When treated with SMZ/TMP, Cxcr2-/- mice infected with RRV to induce experimental biliary atresia showed further enrichment of Corynebacterium, Anaerococcus and Streptococcus. Among these, Anaerococcus lactolyticus was significantly associated with a suppression of biliary injury, cholestasis, and survivability. These results suggest that the postnatal development of the intestinal microbiota is an important susceptibility factor for experimental biliary atresia.
Subject(s)
Bile Ducts/injuries , Biliary Atresia/metabolism , Inflammation/metabolism , Microbiota , Receptors, Interleukin-8B/metabolism , Animals , Biliary Atresia/microbiology , Disease Models, Animal , Female , Gene Expression Profiling , Lactation , Linear Models , Macaca mulatta , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Transgenic , Phenotype , Polymerase Chain Reaction , Pregnancy , Pregnancy, Animal , RNA, Ribosomal, 16S/genetics , Receptors, Interleukin-8B/genetics , Rotavirus , Signal Transduction , Sulfamethoxazole/administration & dosage , Trimethoprim/administration & dosageABSTRACT
The tissue distribution and depletion of sulfamethoxazole (SMZ) and trimethoprim (TMP) were studied in Pacific white shrimp, Litopenaeus vannamei, after single-dose and multiple-dose oral administration of SMZ-TMP (5:1) via medicated feed. In single-dose oral administration, shrimps were fed once at a dose of 100 mg/kg (drug weight/body weight). In multiple-dose oral administration, shrimps were fed three times a day for three consecutive days at a dose of 100mg/kg. The results showed the kinetic characteristic of SMZ was different from TMP in Pacific white shrimp. In the single-dose administration, the SMZ was widely distributed in the tissues, while TMP was highly concentrated in the hepatopancreas. The t1/2z values of SMZ were larger and persist longer than TMP in Pacific white shrimp. In the multiple-dose administration, SMZ accumulated well in the tissues, and reached steady state level after successive administrations, while TMP did not. TMP concentration even appeared the downward trend with the increase of drug times. Compared with the single dose, the t1/2z values of SMZ in hepatopancreas (8.22-11.33h) and muscle (6.53-10.92h) of Pacific white shrimps rose, but the haemolymph dropped (13.76-11.03) in the multiple-dose oral administration. Meanwhile, the corresponding values of TMP also rose in hepatopancreas (4.53-9.65h) and muscle (2.12-2.71h), and declined in haemolymph (7.38-5.25h) following single-dose and multiple-dose oral administration in Pacific white shrimps. In addition, it is worth mentioning that the ratios of SMZ and TMP were unusually larger than the general aim ratio.
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Penaeidae/metabolism , Sulfamethoxazole/pharmacokinetics , Trimethoprim/pharmacokinetics , Animals , Anti-Bacterial Agents/administration & dosage , Hemolymph/metabolism , Hepatopancreas/metabolism , Muscles/metabolism , Sulfamethoxazole/administration & dosage , Trimethoprim/administration & dosageSubject(s)
Nocardia Infections/diagnosis , Nocardia/isolation & purification , Pleural Effusion/diagnostic imaging , Administration, Intravenous , Adult , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Ciprofloxacin/administration & dosage , Ciprofloxacin/therapeutic use , Humans , Immunocompetence , Male , Nocardia Infections/drug therapy , Sulfamethoxazole/administration & dosage , Sulfamethoxazole/therapeutic use , Treatment OutcomeABSTRACT
Trans-generational effects are increasingly used to indicate long-term influences of environmental pollutants. However, such studies can be complex and yield inconclusive results. In this study, the trans-generational effects of sulfamethoxazole (SMX) on Caenorhabditis elegans on lifespan, reproduction and population growth were tested for 7 consecutive generations, which included gestating generation (F0), embryo-exposed generation (F1), germline-exposed generation (F2), the first non-exposed generation (F3) and the three following generations (F4-F6). Results showed that lifespan was significantly affected by embryo exposure (F1) at 400µm SMX with a value as low as 47% of the control. The reproduction (a total brood size as 49% of the control) and population growth (81% of the control) were significantly affected in germline exposure (F2). Lifespan and reproduction were severely inhibited in non-exposed generations, confirming the real trans-generational effects. Notably, initial reproduction and reproduction duration showed opposite generation-related changes, indicating their interplay in the overall brood size. The population growth rate was well correlated with median lethal time, brood size and initial reproduction, which indicated that the population would increase when the nematodes lived longer and reproduced more offspring within shorter duration.
Subject(s)
Anti-Infective Agents/pharmacology , Caenorhabditis elegans/drug effects , Longevity/drug effects , Reproduction/drug effects , Sulfamethoxazole/pharmacology , Animals , Anti-Infective Agents/administration & dosage , Caenorhabditis elegans/embryology , Caenorhabditis elegans/genetics , Environmental Exposure , Population Growth , Sulfamethoxazole/administration & dosageABSTRACT
A 50-year-old male visited the outpatient clinic and complained of fever, poor oral intake, and weight loss. A chest X-ray demonstrated streaky and fibrotic lesions in both lungs, and chest CT revealed multifocal peribronchial patchy ground-glass opacities with septated cystic lesions in both lungs. Cell counts in the bronchoalveolar lavage fluid revealed lymphocyte-dominant leukocytosis, and further analysis of lymphocyte subsets showed a predominance of cytotoxic T cells and few T helper cells. Video-assisted wedge resection of the left upper lobe was performed, and the histologic examination was indicative of a Pneumocystis jirovecii infection. Trimethoprim-sulfamethoxazole (TMP-SMX) was orally administered for 3 weeks; however, the patient complained of cough, and the pneumonia was aggravated in the follow-up chest X-ray and chest CT. Molecular studies demonstrated mutations at codons 55 and 57 of the dihydropteroate synthase (DHPS) gene, which is associated with the resistance to TMP-SMX. Clindamycin-primaquine was subsequently administered for 3 weeks replacing the TMP-SMX. A follow-up chest X-ray showed that the pneumonia was resolving, and the cough was also alleviated. A positive result of HIV immunoassay and elevated titer of HCV RNA indicated HIV infection as an underlying condition. This case highlights the importance of careful monitoring of patients with P. jirovecii pneumonia (PCP) during the course of treatment, and the molecular study of DHPS mutations. Additionally, altering the anti-PCP drug utilized as treatment must be considered when infection with drug-resistant P. jirovecii is suspected. To the best of our knowledge, this is the first case of TMP-SMX-resistant PCP described in Korea.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Pneumocystis carinii/drug effects , Pneumonia/drug therapy , Sulfamethoxazole/administration & dosage , Trimethoprim/administration & dosage , Drug Resistance, Bacterial , Humans , Lung/diagnostic imaging , Lung/microbiology , Male , Middle Aged , Pneumocystis carinii/genetics , Pneumocystis carinii/isolation & purification , Pneumocystis carinii/physiology , Pneumonia/diagnostic imaging , Pneumonia/immunology , Pneumonia/microbiology , RadiographyABSTRACT
Gallic acid (GA) and its derivatives are anti-inflammatory agents reported to have an effect on osteoarthritis (OA). However, GA has much weaker anti-oxidant effects and inferior bioactivity compared with its derivatives. We modified GA with the introduction of sulfonamide to synthesize a novel compound named JEZ-C and analyzed its anti-arthritis and chondro-protective effects. Comparison of JEZ-C with its sources i.e. GA and Sulfamethoxazole (SMZ) was also performed. Results showed that JEZ-C could effectively inhibit the IL-1-mediated induction of MMP-1 and MMP-13 and could induce the expression of TIMP-1, which demonstrated its ability to reduce the progression of OA. JEZ-C can also exert chondro-protective effects by promoting cell proliferation and maintaining the phenotype of articular chondrocytes, as evidenced by improved cell growth, enhanced synthesis of cartilage specific markers such as aggrecan, collagen II and Sox9. Meanwhile, expression of the collagen I gene was effectively downregulated, revealing the inhibition of chondrocytes dedifferentiation by JEZ-C. Hypertrophy that may lead to chondrocyte ossification was also undetectable in JEZ-C groups. The recommended dose of JEZ-C ranges from 6.25×10-7 µg/ml to 6.25×10-5 µg/ml, among which the most profound response was observed with 6.25×10-6 µg/ml. In contrast, its source products of GA and SMZ have a weak effect not only in the inhibition of OA but also in the bioactivity of chondrocytes, which indicated the significance of this modification. This study revealed JEZ-C as a promising novel agent in the treatment of chondral and osteochondral lesions.
Subject(s)
Gallic Acid/administration & dosage , Inflammation/drug therapy , Osteoarthritis/drug therapy , Sulfamethoxazole/administration & dosage , Sulfonamides/administration & dosage , Antioxidants/metabolism , Cartilage, Articular/drug effects , Cartilage, Articular/growth & development , Cartilage, Articular/pathology , Cell Line , Chondrocytes/drug effects , Gallic Acid/chemical synthesis , Humans , Inflammation/pathology , Osteoarthritis/pathology , Sulfamethoxazole/chemical synthesisABSTRACT
A menthol-based solid dispersion was designed to improve the intrinsic solubility of the poorly soluble sulfamethoxazole- a class II drug molecule of Biopharmaceutics Classification System (BCS) displaying widespread antibacterial activity. Solid dispersions of menthol and sulfamethoxazole were compressed with hydroxypropyl methylcellulose (HPMC) into suitable sulfamethoxazole-loaded matrix tablets for oral drug delivery. The sulfamethoxazole-loaded solid dispersions and compressed tablets were characterized for their physicochemical and physicomechanical properties such as changes in crystallinity, melting point, molecular transitions, and textural analysis for critical analysis of their effects on the solubility and dissolution of sulfamethoxazole. The formulations were further evaluated for swelling, degradation, solubility, and in vitro drug release behavior. In vitro drug release from the sulfamethoxazole-loaded matrix tablets displayed a minimum and maximum fractional release of 0.714 and 0.970, respectively. The tablets further displayed different release rate profiles over the study periods of 12, 16, 48, and 56 h which were attributed to the varying concentrations of menthol within each formulation. Menthol was determined as a suitable hydrophilic carrier for sulfamethoxazole since it functioned as a solubilizing and release-retarding agent for improving the solubility and dissolution of sulfamethoxazole as well as controlling the rate at which it was released.
Subject(s)
Menthol/chemistry , Sulfamethoxazole/chemistry , Tablets , Administration, Oral , Materials Testing , Solubility , Spectroscopy, Fourier Transform Infrared , Sulfamethoxazole/administration & dosageABSTRACT
PURPOSE: To investigate the extent to which clinicians avoid well-established drug-drug interactions associated with warfarin. We hypothesised that clinicians would avoid combining non-steroidal anti-inflammatory drugs (NSAIDs), tramadol and sulfamethoxazole with warfarin. METHODS: A cross-sectional analysis of nationwide dispensing data was performed in Swedish individuals 18 years or older (nâ=â 7,563,649). Odds ratios of interacting NSAIDs, tramadol and sulfamethoxazole versus respective prevalence of comparator drugs codeine, and ciprofloxacin in patients co-dispensed interacting warfarin versus patients unexposed was calculated. RESULTS: The odds of receiving an interacting NSAID versus the comparator codeine was markedly lower in patients with warfarin than in the remaining population (adjusted OR 0.21; 95% CI 0.20 - 0.22). Also, the interacting drugs tramadol and sulfamethoxazole were less common among patients dispensed warfarin as compared to the remaining population, although the decrease was much more modest (adjusted OR 0.83; CI 0.80-0.87 and 0.81; CI 0.73 - 0.90). CONCLUSIONS: In conclusion, Swedish doctors in the vast majority of cases refrain from prescribing NSAIDs to patients already on warfarin. Tramadol and sulfamethoxazole are however rarely avoided.
Subject(s)
Drug Interactions , Guideline Adherence , Warfarin/adverse effects , Adult , Aged , Aged, 80 and over , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Cross-Sectional Studies , Humans , Middle Aged , Odds Ratio , Registries , Retrospective Studies , Sulfamethoxazole/administration & dosage , Sweden , Tramadol/administration & dosage , Warfarin/administration & dosageABSTRACT
The use of antibiotics in both human and veterinary medicine has led to increased presence of these compounds and antibiotic resistance in the environment. In this study, the effect of low, environmentally relevant (